Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance

Zhao, Dujuan; Zhang, Huiyuan; Yang, Shengfeng; He, Wenxiu; Luan, Yuxia

doi:10.1016/j.ijpharm.2016.10.029

Cited by 70 publications

(47 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the coumarin‐6‐loaded liposomes were internalized via the cellular endocytosis mechanism, which bypassed the P‐gp mediated drug efflux and enhanced the effects of drug . In addition, TPGS‐coated liposomes resulted in higher cellular uptake due to nonspecific absorbability via absorption‐mediated endocytosis and inhibition of P‐gp efflux by TPGS …”

Section: Resultsmentioning

confidence: 99%

“…[33] In addition, TPGS-coated liposomes resulted in higher cellular uptake due to nonspecific absorbability via absorptionmediated endocytosis and inhibition of P-gp efflux by TPGS. [18,34]…”

Section: Intracellular Accumulation Of Liposomesmentioning

confidence: 99%

“…TPGS is an amphipathic molecule used in the treatment of cancer cells via nanoparticles and as an emulsifier, stabilizing agent, bioavailability enhancer, solubilizer and P-gp inhibitor. [16][17][18] It has been reported that resveratrol-loaded TPGS-coated liposomes enhanced cellular uptake, significantly increased cytotoxicity in C6 glioma cells and improved the pharmacokinetics and tissue distribution of resveratrol. [19] Furthermore, research has also shown the feasibility of constructing TPGS-coated liposomes, which resulted in amelioration of the permeation of dextran through Caco-2 cells (Transwell â model) without cytotoxic effects.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Fei

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Multidrug resistance (MDR) remains a primary challenge in breast cancer treatment. In the present study, D‐alpha‐tocopheryl polyethylene glycol 1000 succinate (TPGS)‐coated docetaxel‐loaded liposomes were developed as a novel drug delivery system to reverse MDR and enhance breast cancer therapy compared with the traditional liposomes, DSPE‐mPEG‐coated liposomes (stealth liposomes) and commercial Taxotere®. Key findings Liposomes were prepared by thin – film dispersion method. Evaluations were performed using human breast cancer MCF‐7 and resistant MCF‐7/ADR cells. The reversal multidrug‐resistant effect was assessed by P‐gp inhibition assay, cytotoxicity, cellular uptake and apoptosis assay. Results The TPGS‐chol‐liposomes were of an appropriate particle size (140.0 ± 6.0 nm), zeta potential (−0.196 ± 0.08 mv), high encapsulation efficiency (99.0 ± 0.9) and favourable in vitro sustained release. The TPGS‐coated liposomes significantly improved cytotoxicity and increased the intracellular accumulation of docetaxel in both types of breast cancer cells. The TPGS‐coated liposomes were confirmed to induce apoptosis via a synergistic effect between docetaxel and TPGS. It was demonstrated that TPGS enhanced the intracellular accumulation of drug by inhibiting overexpressed P‐glycoprotein. Conclusions The TPGS‐conjugated liposomes showed significant advantages in vitro compared with the PEG‐conjugated liposomes. The TPGS‐conjugated liposomes could reverse the MDR and enhance breast cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Intracellular Accumulation Of Liposomesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Fei

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…The hemolytic ratios of DEX-SS-IND/DOX micelles at various concentrations were all ,4%, suggesting DEX-SS-IND/DOX micelles could not induce red blood cell rupture. 32 Therefore, DEX-SS-IND/DOX micelles were considered to be safe and biocompatible for intravenous administration.…”

Section: The Hemolytic Testmentioning

confidence: 99%

Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer

Zhou¹,

Wang²,

Ying³

et al. 2017

IJN

View full text Add to dashboard Cite

Multidrug resistance (MDR) against chemotherapeutic agents has become one of the major obstacles to successful cancer therapy and MDR-associated proteins (MRPs)-mediated drug efflux is the key factor for MDR. In this study, a redox-responsive polymer based on dextran (DEX) and indomethacin (IND), which could reduce MRPs-mediated efflux of chemotherapeutics, was synthesized, and the obtained polymer could spontaneously form stable micelles with well-defined core-shell structure and a uniform size distribution with an average diameter of 50 nm and effectively encapsulate doxorubicin (DOX); the micelles contain a disulfide bridge (cystamine, SS) between IND and DEX (DEX-SS-IND). In vitro drug release results indicated that DEX-SS-IND/DOX micelles could maintain good stability in a stimulated normal physiological environment and promptly depolymerized and released DOX in a reducing environment. After incubating DEX-SS-IND/DOX micelles with drug-resistant tumor (MCF-7/ADR) cells, the intracellular accumulation and retention of DOX were significantly increased under the synergistic effects of redox-responsive delivery and the inhibitory effect of IND on MRPs. In vitro cytotoxicity showed that DEX-SS-IND/DOX micelles exhibited higher cytotoxicity against MCF-7/ADR cells. Moreover, DEX-SS-IND/DOX micelles showed significantly enhanced inhibition of tumor in BALB/c nude mice bearing MCF-7/ADR tumors and reduced systemic toxicity. Overall, the cumulative evidence indicates that DEX-SS-IND/DOX micelles hold significant promise for overcoming MDR for cancer therapy.

show abstract

“…Specific NDDS could be designed and given more functions according to the unique microenvironment of tumor cells, thereby achieving rapid intracellular drug release and preventing drug efflux. [19][20][21][22][23][24] The redox environment in tumor cells is a typical example. The intracellular reductive environment is the important feature of tumor cells due to the excessive expression of glutathione (GSH) in the cytoplasm.…”

Section: Introductionmentioning

confidence: 99%

Redox-responsive F127-folate/F127-disulfide bond-D-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors

Lin¹,

Zhao²,

Liu³

et al. 2018

IJN

View full text Add to dashboard Cite

Introduction The development of nanodrug carriers utilizing tumor microenvironment has become a hotspot in reversing multidrug resistance (MDR). Materials and methods This study synthesized a redox-sensitive copolymer, Pluronic F127-disulfide bond- d -α-tocopheryl polyethylene glycol 1000 succinate (FSST), through the connection of the reduction-sensitive disulfide bond between F127 and d -α-tocopheryl polyethylene glycol 1000 succinate. This polymer could induce the elevation of reactive oxygen species (ROS) levels, ultimately resulting in cytotoxicity. Moreover, the redox-responsive mixed micelles, F127-folate (FA)/FSST/P123 (FFSSTP), based on FSST, Pluronic F127-FA, and Pluronic P123, were prepared to load paclitaxel (PTX). Results The in vitro release study demonstrated that FFSSTP/PTX accelerated the PTX release through the breakage of disulfide bond in reductive environment. In cellular experiment, FFSSTP/PTX induced significant apoptosis in PTX-resistant MCF-7/PTX cells through inhibiting adenosine triphosphate (ATP)-binding cassette proteins from pumping out PTX by interfering with the mitochondrial function and ATP synthesis. Furthermore, FFSSTP/PTX induced apoptosis through elevating the intracellular levels of ROS. Conclusion FFSSTP could become a potential carrier for the treatment of MDR tumors.

show abstract

Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance

Cited by 70 publications

References 55 publications

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer

Redox-responsive F127-folate/F127-disulfide bond-D-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors

Contact Info

Product

Resources

About

Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance

Cited by 70 publications

References 55 publications

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells

Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer

Redox-responsive F127-folate/F127-disulfide bond-D-&alpha;-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors

Contact Info

Product

Resources

About

Redox-responsive F127-folate/F127-disulfide bond-D-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors